A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization with Burkholderia spp.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs OligoG (Primary)
- Indications Burkholderia infections; Cystic fibrosis
- Focus Pharmacodynamics
- Sponsors AlgiPharma
- 03 Feb 2017 Last checked against ClinicalTrials.gov record.
- 26 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 May 2017.
- 26 Jan 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.